Close Navigation
AI Daily: Nvidia CEO ‘surprised’ AMD offered 10% stake in OpenAI deal

AI Daily: Nvidia CEO ‘surprised’ AMD offered 10% stake in OpenAI deal

Posted October 9, 2025 at 10:30 am

Jessica de Sa-Mota
The Fly

OpenAI and Anthropic debate on using investor funds to settle lawsuits

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly:

OPENAI DEAL: 

Nvidia (NVDA) CEO Jensen Huang said AMD’s (AMD) deal to offer 10% of itself to OpenAI is “surprising” and “imaginative” considering AMD was “so excited about” its next-generation chip, the executive told CNBC’s “Squawk Box” in an interview. “I’m surprised that they would give away 10% of the company before they even built it. And so anyhow, it’s clever, I guess,” Huang said. OpenAI has committed to purchase 6 gigawatts worth of AMD chips over multiple years, including its forthcoming MI450 series, and OpenAI will receive warrants for up to 160 million AMD shares, with vesting milestones based on deployment volume and AMD’s share price.

LAWSUITS: 

Microsoft-backed (MSFT) OpenAI and Anthropic are debating on using investor funds to settle any potential claims from multibillion-dollar lawsuits, Cristina Criddle and Lee Harris of The Financial Times report. While both companies have traditional business insurance coverage, insurance professionals have said AI model providers may struggle to secure protection for the full damages they may need to pay in the future. OpenAI is using Aon (AON) for help and has secured up to $300M for AI risks, people familiar with the company’s policy told the Times.

FUNDING ROUND: 

xAI, the artificial intelligence startup backed by Tesla (TSLA) CEO Elon Musk, is raising more financing than previously planned, including an equity investment from Nvidia, to bring its ongoing funding round to $20B, Bloomberg’s Carmen Arroyo and Ed Ludlow report, citing people familiar with the matter. The financing, which includes equity and debt, will be linked to the Nvidia GPUs that the AI startup intends to use in Colossus 2, the name of its biggest data center site, the authors note.

AI ENTERPRISE PLATFORM: 

Hoth Therapeutics (HOTH) announced it has expanded its artificial intelligence initiative through a new Nvidia AI Enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics. Under the new entitlement and renewal agreement, Hoth Therapeutics has secured annual Nvidia AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.

Originally Posted October 8, 2025 – AI Daily: Nvidia CEO ‘surprised’ AMD offered 10% stake in OpenAI deal

Join The Conversation

For specific platform feedback and suggestions, please submit it directly to our team using these instructions.

If you have an account-specific question or concern, please reach out to Client Services.

We encourage you to look through our FAQs before posting. Your question may already be covered!

Leave a Reply

Disclosure: Interactive Brokers Third Party

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from The Fly and is being posted with its permission. The views expressed in this material are solely those of the author and/or The Fly and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

IBKR Campus Newsletters

This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.